Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Transcatheter Edge-to-Edge Repair (TEER)
Treatment for Non-rheumatic degenerative mitral valve disease
Effectiveness
75%
Safety Score
60%
Clinical Trials
100
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Time to Effect
1-3 months for symptom improvement
Treatment Duration
One-time procedure
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$2,000
Side Effect Mgmt:$750
Total Annual:$2,750
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$90,000/QALY
QALYs Gained
3
Outcome-Based Costs
Cost per Responder
$3,437.5
Cost per Remission
$5,000
Comparison vs Medical Management
Cost Difference
+$90,000/year
More expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
No dominance
Transcatheter Edge-to-Edge Repair (TEER) Outcomes
for Non-rheumatic degenerative mitral valve disease
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+80%
Remission Rate
+55%
Common Side Effects
Vascular complications (access site)
+7%
New-onset Atrial Fibrillation
+7%
MR recurrence/residual MR
+15%
Single-leaflet device thrombosis
+0.5%
In-hospital Mortality
+3.5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov